Spyre Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Spyre Therapeutics

09/05/2024 22:31

* Spyre Therapeutics Inc  SYRE.OQ  reported a quarterly
adjusted
loss of $1.20​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-5.00.  The mean expectation of seven analysts for the
quarter was for a loss of $1.17 per share. Wall Street expected
results to range from $-1.78 to -85 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Spyre Therapeutics Inc's reported EPS for the quarter was
a loss
of $1.20​.
    * The company reported a quarterly loss of $43.86 million.
    * Spyre Therapeutics Inc shares had fallen by 12.9% this
quarter and gained 53.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 112.1% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Spyre
Therapeutics Inc is $50.00 
This summary was machine generated from LSEG data May 9 at 09:31
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.17          -1.20          Missed
 Dec. 31 2023      -0.78          -4.05          Missed
 Sep. 30 2023      -0.84          -9.34          Missed
 Jun. 30 2023      -4.50          -41.50         Missed